Unterehmen auf Watchlist setzen
MiMedx Group
ISIN: US6024961012
WKN: A0MS6X
Über
Unternehmensprofil
Tipp: Investor-Alerts aktivieren
Lassen Sie sich bei neuen Publikationen informieren
Tipp: AI-Factsheet

Corporate News meets AI! 
Analyse der Inhalte und Zusammenfassung

MiMedx Group · ISIN: US6024961012 · PR Newswire (ID: 20240826NE89858)
26 August 2024 03:30PM

DEFENDANT FIGHTS BACK AGAINST MiMEDX "BLATANT INTIMIDATION" NON-COMPETE SUIT


Ex-MiMedx Employee Caralyn Gargan Files Counterclaims for "Predatory Sales Practices" and "Incentivized Fraud" per Mintz Attorneys

MARIETTA, Ga., Aug. 26, 2024 /PRNewswire/ -- One of 10 defendants who were sued earlier this year by MiMedx Group, Inc. (NASDAQ: MDXG) today filed counterclaims against the placental biologics company.  Caralyn Gargan, a former MiMedx employee, filed the action against MiMedx for "predatory sales practices" and "incentivized fraud, including Medicare fraud." Gargan also formally presented her answers and defenses to MiMedx's lawsuit which claimed that the 10 former employees, who recently left the company, allegedly breached their contractual obligations to MiMedx. The filing describes the MiMedx suit as a "blatant intimidation tactic."

Specifically, the counterclaims by Gargan allege that MiMedx "engaged in and has directed members of its sales team including [the former employee] to engage in, predatory sales practices aimed at increasing its revenue by incentivizing fraud on the United States government, including Medicare fraud."

The claims reference a warning letter issued by the FDA to MiMedx's CEO, Joseph H. Capper, concerning its AXIOFILL product on December 20, 2023, and assert that the former employee and others "became increasingly uncomfortable about MiMedx senior leadership's direction to sell AxioFill, even though it had not been approved by (or even submitted to) the FDA for FDA Premarket Approval."

The claims filed by Gargan's attorneys at Mintz and Fellows Labriola allege that she left MiMedx after "MiMedx tried to compel its employees to continue selling a product that the U.S. Food and Drug Administration ('FDA') determined could not lawfully be marketed without prior FDA approval."

Today's counterclaims come on the heels of another filed earlier this month on behalf of another former MiMedx employee, Lora Whooley. To read the Gargan claim please click HERE. To read the Whooley claim, please click here HERE.

Cision View original content:https://www.prnewswire.com/news-releases/defendant-fights-back-against-mimedx-blatant-intimidation-non-compete-suit-302230456.html

SOURCE Mintz

Visuelle Wertentwicklung / Kursverlauf · MiMedx Group
Smarte Analyse- und Recherchewerkzeuge finden Sie hier.
This publication was provided by our content partner PR Newswire
PR Newswire
via PR Newswire - Newsfeed
Cision ©2024
PR Newswire
Kontakt:
300 S Riverside Plaza, Chicago, Illinois, USA
+001 (0) 888-776-0942